Bruker acquires preclinical, molecular software provider

By staff writers

July 8, 2019 -- MRI developer Bruker has acquired preclinical and molecular imaging software firm PMOD Technologies. Details of the transaction were not disclosed.

PMOD Technologies' vendor-neutral software can be used to analyze PET studies in neurology, cardiology, and oncology in preclinical and human molecular imaging research settings. The company's focus is on molecular quantification and pharmacokinetic modeling. Based in Zurich, PMOD Technologies was founded in 2003 as a spin-off from University Hospital Zurich and has a development team in Warsaw, Poland.

With the acquisition, Bruker expands its portfolio to now include ParaVision 360 and PMOD for MRI and nuclear molecular imaging translational research.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking